Search our Database of Scientific Publications and Authors

I’m looking for a

    2501 results match your criteria Cutaneous B-Cell Lymphoma

    1 OF 51

    A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Oncologist 2018 Feb 7. Epub 2018 Feb 7.
    Yale University School of Medicine, New Haven, Connecticut, USA.
    Lessons Learned: Clofarabine can be active in relapsed and refractory lymphoid malignancies on a weekly dosing schedule.Responses were seen in patients with T-cell lymphomas, including cutaneous T-cell lymphoma, but not in patients with aggressive B-cell lymphomas.

    Background: Clofarabine is a second-generation purine nucleoside analog currently approved for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia. Read More

    Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey.
    Turk J Gastroenterol 2018 Jan;29(1):87-91
    Department of Pediatric Gastroenterology, Hepatology and Nutrition, Ege University School of Medicine, İzmir, Turkey.
    Background/aims: A liver transplant is the preferred treatment for patients with end-stage liver disease, as it usually results in longterm survival. However, due to the use of chronic immunosuppressive therapy, which is necessary to prevent rejection, de novo cancer is a major risk after transplantation. The aim of this study was to assess the incidence of post-transplant malignancies in children after liver transplantations. Read More

    Primary skeletal muscle lymphoma: A case report.
    Mol Clin Oncol 2018 Jan 3;8(1):80-82. Epub 2017 Nov 3.
    Department of Internal Medicine, Erzurum Regional Training and Research Hospital, Erzurum 25040, Turkey.
    Primary lymphomas of the bone or skeletal muscle are rare. Three mechanisms of lymphomatous involvement of the muscle have been described, namely direct invasion from adjacent involved lymph nodes or bone, metastatic spread and, least commonly, primary muscle lymphoma. We herein present a rare case of primary mucle non-Hodgkin lymphoma with a description if the associated clinicopathological findings and a review of the relevant literature. Read More

    Cutaneous diffuse large B-cell lymphoma.
    Clin Case Rep 2018 Jan 28;6(1):228-229. Epub 2017 Nov 28.
    Haematology DepartmentCentro Hospitalar Vila Nova de Gaia/EspinhoRua Conceição Fernandes4434-502Vila Nova de GaiaPortugal.
    Cutaneous diffuse large B-cell lymphoma accounts for ~6% of all cutaneous lymphomas. It is associated with poor prognosis, and solitary lesions are relatively rare. It often requires an aggressive approach with multi-agent chemotherapy and radiotherapy. Read More

    Drug induced pseudolymphoma.
    Semin Diagn Pathol 2018 Jan 17. Epub 2018 Jan 17.
    Regional Medical Laboratory, 4142 South Mingo Road, Tulsa, OK 74146-3632, United States.
    Atypical lymphocytic infiltrates of the skin comprise a broad spectrum of entities ranging from benign infiltrates to those that are malignant. Many of these infiltrates are in fact reactive lymphomatoid ones related to drug therapy falling under the general category of drug associated pseudolymphoma. Within this nosologic umbrella are nodular and diffuse infiltrates resembling low grade T and B cell lymphoma consistent with lymphocytoma cutis, drug associated reversible T cell dyscrasias which draw a strong morphologic and phenotypic parallel with mycosis fungoides and the various pre-lymphomatous T cell dyscrasias, and angiocentric CD30 positive infiltrates mirroring lymphomatoid papulosis. Read More

    Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases.
    Intern Med 2018 Jan 11. Epub 2018 Jan 11.
    Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Japan.
    Patients with mycosis fungoides (MF), the most common subtype of primary cutaneous T-cell lymphoma, have an increased risk of developing secondary malignancies. We herein report two rare cases of MF concurring with diffuse large B cell lymphoma (B lymphoid lineage) and acute myeloid leukemia (myeloid lineage) in two otherwise healthy elderly patients. Potential etiologic factors, including the impact of the therapy-associated inflammatory response on the development of secondary tumors in patients with MF, are discussed. Read More

    Dermoscopic characterization of cutaneous lymphomas: a pilot survey.
    Int J Dermatol 2018 Mar 10;57(3):339-343. Epub 2018 Jan 10.
    Department of Dermatology, University of Iowa Hospitals & Clinics, Iowa City, IA, USA.
    Background: While substantial dermoscopic analysis of melanocytic lesions has been performed, dermoscopic characterization of cutaneous lymphoid proliferations has been limited. Cutaneous lymphoma, particularly early mycosis fungoides (MF) and its variants, is often challenging to clinically and pathologically distinguish from inflammatory processes of the skin. This study aimed to survey the dermoscopic findings of cutaneous lymphomas and to discern whether any patterns might potentially serve as specific signatures. Read More

    Image Gallery: Metachronic occurrence of primary cutaneous marginal zone B-cell lymphoma and primary cutaneous Rosai-Dorfman disease in the same patient.
    Br J Dermatol 2017 Dec;177(6):e355
    Department of Pathology, University Hospital of Gran Canaria 'Doctor Negrín', Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Canary Islands, Spain.

    Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor alpha therapy.
    J Am Acad Dermatol 2018 Jan 4. Epub 2018 Jan 4.
    Department of Dermatology, Northwestern University, Feinberg School of Medicine, Northwestern Medicine, Chicago, IL. Electronic address:
    Background: Cutaneous lymphoma (CL) diagnosed after anti-tumor necrosis factor (TNF)α therapy has been reported in the literature, yet a clear link between both events remains elusive.

    Objective: To review our experience with CL diagnosed during or after the use of anti-TNFα therapies.

    Methods: This is a multicenter retrospective study and a literature review. Read More

    Primary Cutaneous B-cell Lymphomas: Case Report of Two Cases.
    Indian J Dermatol 2017 Nov-Dec;62(6):675
    Department of Pathology, Armed Forces Medical College, Pune, Maharashtra, India.
    Primary cutaneous lymphomas are a unique, heterogeneous group of lymphoproliferative disorders which have a primary cutaneous manifestation in the absence of systemic involvement of lymph nodes, bone marrow, or visceral organs at the time of diagnosis. Among the primary cutaneous lymphomas, B-cell lymphoma is much less common and accounts for 20%-25% of cases. Primary cutaneous diffuse large B-cell lymphomas (PCDLBCLs) are aggressive neoplasms with poor prognosis. Read More

    Necrotizing fasciitis associated with primary cutaneous B-cell lymphoma. A case report.
    G Chir 2017 May-Jun;38(3):130-134
    Necrotizing fasciitis is a rapidly progressive and life-threatening infection of the deeper skin layers and subcutaneous tissues that moves along the facial planes.

    Objectives: We present the rare case of a patient with necrotizing fasciitis associated with high malignancy b-cell lymphoma. Our purpose is to investigate the probable connection between the two pathologies and evaluate the importance of early surgical intervention. Read More

    A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Mult Scler Relat Disord 2018 Jan 16;19:115-117. Epub 2017 Nov 16.
    Division of Hematology, Mayo Clinic, USA. Electronic address:
    The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it. Read More

    Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study.
    Eur J Dermatol 2017 Nov 24. Epub 2017 Nov 24.
    Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
    Background: Primary cutaneous lymphomas (PCLs) are a rare group of extranodal non-Hodgkin lymphomas, and epidemiological data in Mediterranean countries are scarce.

    Objective: To investigate the incidence and characteristics of PCL in a single tertiary referral centre in Italy.

    Materials & Methods: A total of 141 PCL patients, seen over a 10-year follow-up period, were investigated. Read More

    Primary cutaneous follicle center lymphoma.
    An Bras Dermatol 2017 Sep-Oct;92(5):701-703
    Department of dermatology at Universidade do Estado do Pará (UEPA) - Belém (PA), Brazil.
    Cutaneous lymphomas are classified according to their cellular origin into T-cell lymphoma and B-cell lymphoma. The annual incidence rate is 0.3 per 100,000 population. Read More

    Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Cell Cycle 2017 Nov 20:1-29. Epub 2017 Nov 20.
    a Oncoceutics, Inc. , Philadelphia , PA.
    ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1-8 µM) dose- and time-dependent efficacy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard of care (dexamethasone in MM) and primary samples. Read More

    Mutations in CoagulationAre Associated with More Favorable Outcome in Patients with Cutaneous Melanoma.
    TH Open 2017 Jul;1(2):e113-e121
    Divisions of Laboratory Medicine, The University of Alabama at Birmingham, AL 35249.
    Coagulation factor VIII (FVIII), von Willebrand factor (VWF), and ADAMTS13 play an important role in regulation of normal hemostasis. However, little is known about their roles in patients with malignancy, particularly with cutaneous melanoma. Whole genome sequencing data are available for 25,719 cases in 126 cancer genomic studies for analysis. Read More

    Primary cutaneous B-cell lymphoma: narrative review of the literature.
    G Ital Dermatol Venereol 2017 Nov 16. Epub 2017 Nov 16.
    Dermatology Unit, IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
    Primary Cutaneous B-cell Lymphomas comprehend a group of lymphoproliferative disorders characterized by being monoclonal proliferations of B-cell primarily involving the skin. Despite being recognized as autonomous and distinct clinico-pathologic entities since the late 80s, their classification is still an ongoing matter of debate. At the moment, WHO classification recognizes three disorders: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type. Read More

    PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Am J Surg Pathol 2018 Mar;42(3):326-334
    INSERM U1053, Team 3 Oncogenesis of Cutaneous Lymphomas.
    As checkpoint molecules' inhibition may represent a therapeutic option in relapsing cases, we assessed programmed death ligands' (PD-L1/PD-L2) expression in a series of 29 primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) cases. Double immunostaining for either PD-L1 or PD-L2 was associated either with PAX5 staining to evaluate tumor cells or with CD68 or CD163 staining for macrophages. The microenvironment of PCDLBCL-LT was characterized by immunostainings for CD3 (tumor-infiltrating lymphocytes), FOXP3 (regulatory T cells), programmed cell death-1, and CD33 (myeloid-derived suppressor cells). Read More

    Hodgkin's lymphoma arising in a case of mycosis fungoides: An unusual association.
    Indian J Dermatol Venereol Leprol 2017 Nov 3. Epub 2017 Nov 3.
    Department of Pathology, Vardhman Mahavir Medical College, Safdarjung Hospital, New Delhi, India.
    Mycosis fungoides is a cutaneous T-cell lymphoma with a high risk for developing secondary malignancies, especially B-cell lymphoproliferative disorders. About 40 cases of Hodgkin's lymphoma associated with mycosis fungoides have been reported in literature till date. We report a case of a 35-year-old gentleman who presented with intensely itchy reddish lesions all over the body. Read More

    Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T-cell and B-cell lymphoproliferative disorders.
    J Cutan Pathol 2018 Jan 22;45(1):39-47. Epub 2017 Nov 22.
    Department of Dermatology, University of Iowa, Iowa City, Iowa.
    Background: Appropriate use criteria have been developed for many tests using expert judgment, evidence-based practice and clinical experience. In this context, we report the opinions of practitioners about clonality assays in various clinical scenarios where cutaneous lymphoma is suspected.

    Methods: An Appropriate Use Criteria Task Force sponsored by the American Society of Dermatopathology (ASDP) synthesized clinical scenarios for cutaneous lymphoproliferative disorders (LPDs). Read More

    Pachyderma in Primary Cutaneous NK and T-Cell Lymphoma and Leukemia Cutis.
    Case Rep Dermatol 2017 Sep-Dec;9(3):151-157. Epub 2017 Sep 11.
    Department of Dermatology, Liège University Hospital, Liège, Belgium.
    Background: Pachyderma is defined as severely thickened skin with deep folds and is occasionally observed with primary cutaneous NK and T-cell lymphoma (pCNKTCL), primary cutaneous B-cell lymphoma (pCBCL), and leukemia cutis (LC).

    Aim: To describe the clinical, histological, and therapeutic particularities of a series of pCNKTCL, pCBCL, and LC patients with pachyderma.

    Results: In a series of pCNKTCL (= 70), pCBCL (= 12), and LC (= 2) patients followed up during 9 years, 6 cases of pachyderma were observed. Read More

    Bilateral upper and lower eyelid margin swelling and madarosis due to lymphoma.
    Surv Ophthalmol 2017 Oct 3. Epub 2017 Oct 3.
    Department of Ophthalmology of the Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; Department of Ophthalmology, The Ophthalmic Plastic and Reconstructive Surgery Service, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
    Over a 2-year period, swellings of all 4 eyelid margins developed in a 32-year-old woman and was accompanied by complete loss of eyelashes. An inflammatory dermatologic condition was considered the most likely cause. A full-thickness right lower eyelid biopsy revealed a multinodular lymphoid tumor at the eyelid margin which immunophenotypically and genetically was diagnosed as an extranodal marginal zone lymphoma. Read More

    Frequent immunoglobulin G4 expression in a common variant of primary cutaneous marginal zone B-cell lymphoma.
    Australas J Dermatol 2017 Oct 4. Epub 2017 Oct 4.
    Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
    Immunoglobulin (Ig)G4 expression was recently observed in a proportion of primary cutaneous marginal zone B-cell lymphoma (PCMZL) with plasmacytic differentiation. IgG4-related disease is characterised by polyclonal lymphoplasmacytic infiltration with IgG4 expression, storiform fibrosis and obliterative phlebitis in histopathology. Here we report three cases of common variants of PCMZL with predominant and varied IgG4 expression, suggesting there is an underlying clonal progression between these two entities. Read More

    Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.
    South Asian J Cancer 2017 Jul-Sep;6(3):129-131
    Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.
    Background: T-cell lymphomas with anaplastic morphology typically comprise of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL), ALK-negative ALCL (ALK- ALCL), and primary cutaneous ALCL (PC-ALCL). However, other entities such as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymphoma, and undifferentiated carcinoma can also show similar anaplastic features.

    Aims: To study the clinical features and histological spectrum of ALCL and emphasize the role of immunohistochemistry (IHC) in their diagnosis and categorization. Read More

    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood 2017 11 2;130(19):2073-2083. Epub 2017 Oct 2.
    Department of Dermatology and.
    The presence and degree of peripheral blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome. Available systemic therapies for CTCL may variably decrease tumor burden and improve quality of life, but offer limited effects on survival; thus, novel approaches to the treatment of advanced stages of this non-Hodgkin lymphoma are clearly warranted. Mutational analyses of CTCL patient peripheral blood malignant cell samples suggested the antiapoptotic mediator B-cell lymphoma 2 (BCL2) as a potential therapeutic target. Read More


    Cutaneous Richter Syndrome Mimicking Primary Cutaneous CD4-Positive Small/Medium T-cell Lymphoma: Case Report and Review of the Literature.
    Am J Dermatopathol 2017 Sep 12. Epub 2017 Sep 12.
    Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
    Richter syndrome represents the transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma into an aggressive large B-cell lymphoma. Skin involvement is exceptionally rare, with <20 cases reported and its presence as the first presentation of CLL/small lymphocytic lymphoma, as an isolated skin lesion has never been described. Primary cutaneous CD4-positive small/medium T-cell lymphoma (CD4 PCSM-TCL) characteristically presents with a dense dermal infiltrate consisting primarily of small-/medium-sized pleomorphic T-cells and less than 30% large pleomorphic cells. Read More

    From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
    Recent Pat Anticancer Drug Discov 2017 Nov;12(4):283-295
    "Lucian Blaga" University of Sibiu, Faculty of Medicine, Spitalul Clinic Judetean de Urgenta Sibiu, str Lucian Blaga, nr 2A, Sibiu, 550169 Sibiu, Romania.
    Background: Notable progress has been made in chemo- and immunotherapy of B-cell lymphomas, but less in the treatment of T-cell lymphomas.

    Objective: Histone deacetylases inhibitors are a potentially useful therapeutic mean, as an epigenetic dysregulation is present in lymphomas, and especially in T-cell types. We aimed to study the progress made in this area. Read More

    Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphomaand in immunodeficient mice.
    Oncoimmunology 2017 20;6(9):e1341031. Epub 2017 Jun 20.
    Department of Pediatrics, New York Medical College, Valhalla, NY.
    Facilitating the development of alternative targeted therapeutic strategies is urgently required to improve outcome or circumvent chemotherapy resistance in children, adolescents, and adults with recurrent/refractory de novo mature B-cell (CD20) non-Hodgkin lymphoma, including Burkitt lymphoma (BL). Romidepsin, a histone deacetylase inhibitor (HDACi), has been used to treat cutaneous T-cell lymphoma. We have demonstrated the significant anti-tumor effect of anti-CD20 chimeric antigen receptor (CAR) modified expanded peripheral blood natural killer (exPBNK) against rituximab-sensitive and -resistant BL. Read More

    Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Spontaneous Regression After Biopsy.
    Am J Dermatopathol 2017 Oct;39(10):785-787
    *Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Universidad de Las Palmas de Gran Canaria, Canary Islands, Spain; and †Department of Pathology, Complejo Hospitalario Universitario Insular Materno-Infantil. Canary Islands, Spain.
    Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) represents approximately 20% of cutaneous B lymphomas with an intermediate prognosis. Spontaneous regression is uncommon; there are only 2 published cases. An 83-year-old woman presented 2 orange erythematous nodules on the back of her right leg with an elastic consistency, infiltrated, painful to the touch, and of an 8-month evolution. Read More

    Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
    Clin Lymphoma Myeloma Leuk 2017 Dec 14;17(12):834-851. Epub 2017 Jul 14.
    Department of Dermatology, Stanford University School of Medicine, Stanford, CA. Electronic address:
    The identification of oncogenic drivers of liquid tumors has led to the rapid development of targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and management of these skin toxicities has motivated a novel partnership between dermatologists and oncologists in developing supportive oncodermatology clinics. In this article we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common and significant cutaneous AEs observed during treatment with targeted therapies for hematologic and lymphoid malignancies. Read More

    Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
    Blood Cancer J 2017 Sep 8;7(9):e603. Epub 2017 Sep 8.
    Department of Haematology, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
    CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Read More

    Dermoscopy and the diagnosis of primary cutaneous B-cell lymphoma.
    J Eur Acad Dermatol Venereol 2018 Jan 12;32(1):53-56. Epub 2017 Sep 12.
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY, USA.
    Background: Primary cutaneous B-cell lymphomas (PCBCLs) are frequently misdiagnosed, and a biopsy is needed to attain the correct diagnosis.

    Objective: To characterize the dermoscopic features of PCBCL.

    Methods: In this retrospective observational study, we analysed the pathology reports of 172 newly diagnosed PCBCL for the initial clinical differential diagnosis. Read More

    Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    J Invest Dermatol 2017 Sep;137(9):1831-1833
    Department of Dermatology, Anderson Cancer Center, Houston, Texas, USA.
    Multiple genomic mutations, especially those involving the NF-κB pathway, have been characterized in primary cutaneous large B-cell lymphoma, leg type. However, its genomic profiling remains limited given its rarity. In a recent study, Mareschal et al. Read More

    Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    J Dermatol Sci 2017 Nov 26;88(2):238-246. Epub 2017 Jul 26.
    UMR CNRS 7276, Univ. Limoges,2 avenue Martin Luther King, 87042 Limoges, France.
    Background: Immunophenotype of primary cutaneous diffuse large B-cell lymphoma, leg-type (PCLBCL-LT) suggests a germinal center-experienced B lymphocyte (BCL2+ MUM1+ BCL6+/-).

    Objectives: As maturation history of B-cell is "imprinted" during B-cell development on the immunoglobulin gene sequence, we studied the structure and sequence of the variable part of the genes (IGHV, IGLV, IGKV), immunoglobulin surface expression and features of class switching in order to determine the PCLBCL-LT cell of origin.

    Methods: Clonality analysis with BIOMED2 protocol and VH leader primers was done on DNA extracted from frozen skin biopsies on retrospective samples from 14 patients. Read More

    Regression of diffuse B-cell lymphoma of the leg with intralesional gentian violet.
    Exp Dermatol 2018 Jan 7;27(1):93-95. Epub 2017 Nov 7.
    Department of Dermatology, Atlanta Veterans Administration Medical Center, Emory University School of Medicine, Atlanta, GA, USA.
    In this case report, a patient of primary cutaneous diffuse B-cell lymphoma, leg type was treated with intralesional gentian violet as she was judged to be too medically fragile for conventional chemotherapy due to advanced age and multiple serious comorbidities. Gentian violet (crystal violet/hexamethyl pararosaniline) is a triphenylmethane dye. It has been shown to have an inhibitory effect on NADPH oxidase, an enzyme family which is found in abundance in reactive oxygen-driven tumors such as melanoma and lymphoma. Read More

    Primary Cutaneous B-cell Lymphomas.
    Clin Lab Med 2017 Sep;37(3):547-574
    Department of Pathology, UCSF Dermatopathology Section, University of California, San Francisco, 1701 Divisidero Street, Room 280, San Francisco, CA 94115, USA; Department of Dermatology, UCSF Dermatopathology Section, University of California, San Francisco, 1701 Divisidero Street, Room 280, San Francisco, CA 94115, USA. Electronic address:
    B-cell lymphomas represent approximately 20% to 25% of primary cutaneous lymphomas. Within this group, most cases (>99%) are encompassed by 3 diagnostic entities: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type. In this article, the authors present clinical, histopathologic, immunophenotypic, and molecular features of each of these entities and briefly discuss the rarer intravascular large B-cell lymphoma. Read More

    An unusual presentation of chronic lymphocytic leukemia.
    Avicenna J Med 2017 Jul-Sep;7(3):133-136
    Department of Hematology Oncology, University of Arkansas for Medical Sciences, Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, USA.
    Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a B-cell lymphocytic neoplasm with indolent clinical course. If identified early, observation is opted. Many variables lead to the initiation of treatment. Read More

    Chronic lymphocytic leukemia/small lymphocytic lymphoma with t (2;18) (p12;q21) accompanied by a cutaneous nodule with histological features of diffuse large B-cell lymphoma.
    Rinsho Ketsueki 2017 ;58(7):749-754
    Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine.
    A 73-year-old woman presented a 3-year history of indolent enlargement of cutaneous tumor nodules. Peripheral blood flow cytometry revealed thrombocytopenia (platelets; 85,000/µl) and the presence of an abnormal, small B lymphocyte population (CD5, CD10, CD20, CD22, CD23, FMC7, SmIgλ, and SmIgκ; 4,000/µl). Skin biopsy indicated infiltration of CD5, CD10, CD20, BCL2, BCL6, and cyclin D1atypical large B-cells, suggesting diffuse large B-cell lymphoma. Read More

    Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol 2017 11 2;179(3):439-448. Epub 2017 Aug 2.
    Department of Haematology, University Hospital of Reims and UFR Médecine, Reims, France.
    Histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a rare and poorly reported complication of Waldenström macroglobulinaemia (WM). We performed a retrospective study of 77 WM patients with biopsy-proven transformation to DLBCL. The median time from WM diagnosis to HT was 4·6 years and 16 patients (21%) had never been treated for WM. Read More

    Cutaneous intravascular natural killer/T cell lymphoma with peculiar immunophenotype.
    Histopathology 2017 Dec 10;71(6):994-1002. Epub 2017 Oct 10.
    Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
    Intravascular lymphoma (IVL) is a rare entity. Most cases are a variant of extranodal diffuse large B cell lymphoma, and fewer than 10% of the published cases are of T cell origin. Only intravascular B cell lymphoma is recognized as a distinct entity in the most recent World Health Organization (WHO) classification of lymphoproliferative disorders. Read More

    Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Dermatol Ther 2017 Sep 26;30(5). Epub 2017 Jul 26.
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Organ transplant recipients receiving immunosuppression have an increased risk of developing post-transplant lymphoproliferative diseases (PTLDs). Traditionally, PTLDs refer to Epstein-Barr virus (EBV)-induced B-cell lymphoma. However, post-transplant T-cell lymphoma may also occur and tends to have a poorer response to reduced immunosuppressive therapy. Read More

    1 OF 51